Teva appoints new president, CEO

JERUSALEM — Teva Pharmaceutical Industries has appointed Erez Vigodman as president and CEO, the Israeli drug maker said Thursday.

Vigodman will replace acting president and CEO Eyal Desheh, who will return to his previous position as group EVP and CFO. Desheh took the interim position after the departure of former president and CEO Jeremy Levin in October 2013.

"I would like to welcome Erez to his new position as the CEO of Teva," Teva chairman Phillip Frost said. "As a member of the Teva board since 2009, Erez has a deep understanding of the company and the industry in which it operates, putting him in a strong position to hit the ground running and deliver value for shareholders."

Vigodman plans to leave his current position as president and CEO of agrochemical company Makhteshim Agan Industries on Feb. 6.